Compare VanEck Australian Floating Rate ETF (FLOT) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.73 (market cap $2.27B). The key difference: VanEck Australian Floating Rate ETF is far larger — about 5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is more actively traded (4,179,659 versus 1,872,962). Which is the better fit depends on your goals.
| FLOT | SLS | |
|---|---|---|
Market Cap | $11.24B | $2.27B |
Volume | 1,872,962 | 4,179,659 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $15.46 |
52-Week Low | $50.72 | $1.39 |
Typical Hold Time | 21 Days | — |
Enterprise Value | — | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
